(Q37438148)

20 August 2017

Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients (English)

1 reference

20 August 2017

Deborah A Marshall

2

0 references

Jennifer S. Haas

object named as

Jennifer S Haas

3

0 references

Elena B Elkin

4

object named as

Elena B Elkin

1 reference

20 August 2017

Kathryn A Phillips

1

1 reference

20 August 2017

Su-Ying Liang

5

1 reference

20 August 2017

Michael J Hassett

6

1 reference

20 August 2017

Ilia Ferrusi

7

1 reference

20 August 2017

Jane E Brock

8

1 reference

20 August 2017

Stephanie L Van Bebber

9

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 November 2009

1 reference

20 August 2017

1 reference

20 August 2017

115

1 reference

20 August 2017

22

1 reference

20 August 2017

5166-5174

1 reference

Outcomes-based access: what will it mean for biologics?

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2783254

Closing the evidence gap in the use of emerging testing technologies in clinical practice

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2783254

The meaning of translational research and why it matters

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2783254

The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention?

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2783254

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2783254

HER2 testing in breast cancer: NCCN Task Force report and recommendations.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2783254

Current perspectives on HER2 testing: a review of national testing guidelines

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2783254

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2783254

Realizing the promise of genomics in biomedical research

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2783254

Insurers and 'targeted biologics' for cancer: a conversation with Lee N. Newcomer. Interview by Barbara J. Culliton

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2783254

Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2783254

HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2783254

A review of public policy issues in promoting the development and commercialization of pharmacogenomic applications: challenges and implications

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2783254

Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer

2 October 2018

1 reference

12 December 2020

Three barriers to innovative diagnostics

1 reference

12 December 2020

Influence of health insurance status on inclusion of HER-2/neu testing in the diagnostic workup of breast cancer patients

1 reference

12 December 2020

A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer

1 reference

12 December 2020

Is personalized medicine finally arriving?

1 reference

12 December 2020

Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831

1 reference

12 December 2020

Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer

1 reference

12 December 2020

Concordance between central and local laboratory HER2 testing from a community-based clinical study

1 reference

12 December 2020

Comparative effectiveness: asking the right questions, choosing the right method

1 reference

12 December 2020

Identifiers

DOI

10.1002/CNCR.24574

1 reference

release_bq6vmqr4hngipeuit3uag7hedq

20 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bq6vmqr4hngipeuit3uag7hedq

24 November 2022

mapped directly with Wikidata item

1 reference

20 August 2017

PubMed publication ID

19753618

1 reference